A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 621 participants.

Also called NCT02033889

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 621 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02033889
  • EudraCT 2013-003290-95
Main results
  • Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET) Diabetes, obesity & metabolism, 2018-03 DOI, PubMed 28857451 PubMed links an erratum for this paper. Erratum: PMID 30295414
Other papers using this trial's data
  • Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial Diabetes, obesity & metabolism, 2019-04 DOI, PubMed 30614616, PMC6593724 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02033889. Randomized; double masking; primary purpose treatment. Start 2013-12-13 (actual); primary completion 2017-08-03 (actual). Results posted on 2018-09-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ertugliflozin 5 mg
Intervention (Drug)
Ertugliflozin 15 mg
Intervention (Drug)
Placebo to Ertugliflozin
Intervention (Other)
Glimepiride
Intervention (Drug)
Placebo to Glimepiride
Intervention (Biological)
Basal Insulin
Intervention (Drug)
Metformin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct02033889
Content hash
80f89f3f6d0073d1691bff71cf119f39de7e1118115211668e09f515f53c55dd